Imunon (IMNN) Competitors $0.42 +0.02 (+5.21%) As of 11:41 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMNN vs. STTK, ICCC, VRCA, OKYO, ONCY, CUE, MURA, NBRV, QNCX, and IPSCShould you be buying Imunon stock or one of its competitors? The main competitors of Imunon include Shattuck Labs (STTK), ImmuCell (ICCC), Verrica Pharmaceuticals (VRCA), OKYO Pharma (OKYO), Oncolytics Biotech (ONCY), Cue Biopharma (CUE), Mural Oncology (MURA), Nabriva Therapeutics (NBRV), Quince Therapeutics (QNCX), and Century Therapeutics (IPSC). These companies are all part of the "pharmaceutical products" industry. Imunon vs. Shattuck Labs ImmuCell Verrica Pharmaceuticals OKYO Pharma Oncolytics Biotech Cue Biopharma Mural Oncology Nabriva Therapeutics Quince Therapeutics Century Therapeutics Imunon (NASDAQ:IMNN) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership. Which has more risk & volatility, IMNN or STTK? Imunon has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500. Comparatively, Shattuck Labs has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500. Do analysts rate IMNN or STTK? Imunon presently has a consensus price target of $15.50, indicating a potential upside of 3,590.48%. Shattuck Labs has a consensus price target of $7.50, indicating a potential upside of 617.70%. Given Imunon's stronger consensus rating and higher possible upside, research analysts clearly believe Imunon is more favorable than Shattuck Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Imunon 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.75Shattuck Labs 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.71 Is IMNN or STTK more profitable? Imunon has a net margin of 0.00% compared to Shattuck Labs' net margin of -1,156.46%. Shattuck Labs' return on equity of -61.92% beat Imunon's return on equity.Company Net Margins Return on Equity Return on Assets ImunonN/A -230.05% -128.98% Shattuck Labs -1,156.46%-61.92%-54.49% Do institutionals and insiders believe in IMNN or STTK? 4.5% of Imunon shares are owned by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are owned by institutional investors. 5.0% of Imunon shares are owned by insiders. Comparatively, 10.5% of Shattuck Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has preferable valuation and earnings, IMNN or STTK? Imunon has higher earnings, but lower revenue than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImunon$500K14.74-$19.51M-$1.36-0.31Shattuck Labs$4.61M10.87-$87.30M-$1.39-0.75 Does the media refer more to IMNN or STTK? In the previous week, Imunon had 13 more articles in the media than Shattuck Labs. MarketBeat recorded 13 mentions for Imunon and 0 mentions for Shattuck Labs. Imunon's average media sentiment score of 0.31 beat Shattuck Labs' score of 0.00 indicating that Imunon is being referred to more favorably in the media. Company Overall Sentiment Imunon Neutral Shattuck Labs Neutral Does the MarketBeat Community prefer IMNN or STTK? Shattuck Labs received 14 more outperform votes than Imunon when rated by MarketBeat users. However, 92.59% of users gave Imunon an outperform vote while only 69.64% of users gave Shattuck Labs an outperform vote. CompanyUnderperformOutperformImunonOutperform Votes2592.59% Underperform Votes27.41%Shattuck LabsOutperform Votes3969.64% Underperform Votes1730.36% SummaryImunon beats Shattuck Labs on 11 of the 18 factors compared between the two stocks. Get Imunon News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMNN vs. The Competition Export to ExcelMetricImunonPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.42M$6.45B$5.31B$8.42BDividend YieldN/A2.64%5.21%4.10%P/E Ratio-0.229.0426.7819.69Price / Sales14.74253.23386.97118.34Price / CashN/A65.8538.2534.62Price / Book0.306.406.744.50Net Income-$19.51M$143.98M$3.23B$248.32M7 Day Performance-25.21%1.90%1.49%-0.03%1 Month Performance-51.83%4.01%11.47%12.72%1 Year Performance-70.42%-3.00%16.57%7.38% Imunon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMNNImunon1.5756 of 5 stars$0.42+5.2%$15.50+3,590.5%-72.3%$7.42M$500,000.00-0.2230News CoverageAnalyst ForecastGap UpHigh Trading VolumeSTTKShattuck Labs2.578 of 5 stars$0.99+4.4%$7.50+657.6%-86.1%$47.42M$4.61M-0.65100Gap UpICCCImmuCell0.1755 of 5 stars$5.24+3.4%N/A+29.0%$47.13M$26.49M-10.4870Gap UpVRCAVerrica Pharmaceuticals4.2326 of 5 stars$0.51+15.1%$9.50+1,776.4%-92.7%$46.81M$7.57M-0.2840Analyst RevisionGap DownOKYOOKYO Pharma1.7161 of 5 stars$1.38-4.8%$7.00+407.2%+12.2%$46.69MN/A0.007ONCYOncolytics Biotech1.7184 of 5 stars$0.54+4.0%$4.33+702.5%-62.1%$46.67MN/A-2.0030Analyst ForecastCUECue Biopharma3.8829 of 5 stars$0.75-3.7%$3.00+299.5%-68.1%$46.43M$9.29M-0.8360Gap DownMURAMural Oncology2.3215 of 5 stars$2.64+0.4%$13.00+392.4%-26.8%$45.59MN/A-0.29119Positive NewsGap DownNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070News CoverageAnalyst ForecastQNCXQuince Therapeutics2.901 of 5 stars$1.03+1.0%$8.00+676.7%+19.8%$45.45MN/A-0.8360Analyst DowngradeIPSCCentury Therapeutics2.4917 of 5 stars$0.52-2.3%$4.40+738.6%-80.5%$45.21M$6.59M-0.28170Earnings ReportAnalyst RevisionGap Down Related Companies and Tools Related Companies STTK Competitors ICCC Competitors VRCA Competitors OKYO Competitors ONCY Competitors CUE Competitors MURA Competitors NBRV Competitors QNCX Competitors IPSC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMNN) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMNN Stock Free IMNN Stock Alerts